Also trades as: ADAP (NASDAQ) · $vol 5M
ADAPY OTC
Adaptimmune Therapeutics plc
1W: +45.1%
1M: +48.0%
3M: -5.1%
YTD: +5.6%
1Y: -69.5%
3Y: -95.4%
5Y: -99.4%
$0.04
-0.00 (-2.63%)
Weekly Expected Move ±21.4%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$73M
+48.0% ▲
Capital Expenditures
$3M
+44.3% ▲
5Y CAGR: -2.4%
Free Cash Flow
-$76M
+47.9% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$54M
-243.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$130M | -$158M | -$165M | -$114M | -$71M |
| Depreciation & Amort. | $8M | $7M | $6M | $9M | $11M |
| Stock-Based Comp. | $10M | $21M | $18M | $12M | $12M |
| Change in Working Capital | $56M | $135M | -$2M | -$25M | -$37M |
| Other Non-Cash Items | $2M | $7M | $903K | -$24M | $11M |
| Operating Cash Flow | -$54M | $11M | -$142M | -$141M | -$73M |
| — Investing Activities — | |||||
| Capital Expenditures | -$3M | -$9M | -$30M | -$5M | -$3M |
| Acquisitions (Net) | $0 | $207K | $78M | $45M | $0 |
| Investment Purchases | -$381M | -$140M | -$48M | -$76M | -$100M |
| Investment Sales | $105M | $224M | $167M | $211M | $44M |
| Other Investing | -$565K | -$207K | -$78M | $1M | $130K |
| Investing Cash Flow | -$279M | $76M | $89M | $177M | -$59M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | $50M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $6M | $759K | $50K | $256K | $77K |
| Financing Cash Flow | $340M | $3M | $13M | $880K | $79M |
| Net Change in Cash | $7M | $90M | -$42M | $37M | -$54M |
| Cash End of Period | $61M | $152M | $110M | $147M | $93M |
| Free Cash Flow | -$56M | $2M | -$172M | -$146M | -$76M |